| Abbreviations |
|
2 | (2) |
|
Table 1A Clinical Approach to Initial Choice of Antimicrobial Therapy |
|
|
4 | (59) |
|
Table 2 Recommended Antimicrobial Agents Against Selected Bacteria |
|
|
63 | (3) |
|
Table 3 Suggested Duration of Antibiotic Therapy in Immunocompetent Patients |
|
|
66 | (1) |
|
Table 4 Comparison of Antibacterial Spectra |
|
|
67 | (6) |
|
Table 5 Treatment Options for Selected Highly Resistant Bacteria |
|
|
73 | (2) |
|
Table 6 Suggested Management of Suspected or Culture-Positive Community-Associated Methicillin-Resistant S. Aureus (CA-MRSA) Infections |
|
|
75 | (2) |
|
Table 7 Methods for Drug Desensitization |
|
|
77 | (1) |
|
Table 8 Risk Categories of Antimicrobics in Pregnancy |
|
|
78 | (1) |
|
Table 9A Selected Pharmacologic Features of Antimicrobial Agents |
|
|
79 | (7) |
|
Table 9B Pharmacodynamics of Antibacterials |
|
|
86 | (1) |
|
Table 9C Cytochrome P450 Interactions of Antimicrobials |
|
|
86 | (1) |
|
Table 10A Selected Antibacterial Agents---Adverse Reactions---Overview |
|
|
87 | (4) |
|
Table 10B Antimicrobial Agents Associated with Photosensitivity |
|
|
91 | (1) |
|
Table 10C Antibiotic Dosage and Side-Effects |
|
|
92 | (9) |
|
Table 10D Aminoglycoside Once-Daily and Multiple Daily Dosing Regimens |
|
|
101 | (1) |
|
Table 11A Treatment of Fungal Infections---Antimicrobial Agents of Choice |
|
|
102 | (12) |
|
Table 11B Antifungal Drugs: Dosage, Adverse Effects, Comments |
|
|
114 | (3) |
|
Table 11C At A Glance Summary of Suggested Antifungal Drugs Against Treatable Pathogenic Fungi |
|
|
117 | (1) |
|
Table 12A Treatment of Mycobacterial Infections |
|
|
118 | (10) |
|
Table 12B Dosage and Adverse Effects of Antimycobacterial Drugs |
|
|
128 | (3) |
|
Table 13A Treatment of Parasitic Infections |
|
|
131 | (10) |
|
Table 13B Dosage and Selected Adverse Effects of Antiparasitic Drugs |
|
|
141 | (3) |
|
Table 13C Parasites that Cause Eosinophilia (Eosinophilia In Travelers) |
|
|
144 | (1) |
|
Table 13D Sources for Hard-to-Find Antiparasitic Drugs |
|
|
144 | (1) |
|
Table 14A Antiviral Therapy (Non-HIV) |
|
|
145 | (13) |
|
Table 14B Antiviral Drugs (Non-HIV) |
|
|
158 | (4) |
|
Table 14C At A Glance Summary of Suggested Antiviral Agents Against Treatable Pathogenic Viruses |
|
|
162 | (1) |
|
Table 14D Antiretroviral Therapy in Treatment-Naive Adults (HIV/AIDS) |
|
|
163 | (10) |
|
Table 14E Antiretroviral Drugs and Adverse Effects (HIV/AIDS) |
|
|
173 | (3) |
|
Table 15A Antimicrobial Prophylaxis for Selected Bacterial Infections |
|
|
176 | (1) |
|
Table 15B Surgical Antibiotic Prophylaxis |
|
|
177 | (4) |
|
Table 15C Antimicrobial Prophylaxis for the Prevention of Bacterial Endocarditis in Patients with Underlying Cardiac Conditions |
|
|
181 | (1) |
|
Table 15D Management of Exposure to HIV-1 and Hepatitis B and C |
|
|
182 | (3) |
|
Table 15E Prevention of Selected Opportunistic Infections in Human Hematopoietic Cell Transplantation (HCT) or Solid Organ Transplantation (SOT) in Adults With Normal Renal Function |
|
|
185 | (2) |
|
Table 16 Pediatric Dosages of Selected Antibacterial Agents |
|
|
187 | (1) |
|
Table 17A Dosages of Antimicrobial Drugs in Adult Patients with Renal Impairment |
|
|
188 | (8) |
|
Table 17B No Dosage Adjustment with Renal Insufficiency by Category |
|
|
196 | (1) |
|
Table 18 Antimicrobials and Hepatic Disease: Dosage Adjustment |
|
|
196 | (1) |
|
Table 19 Treatment of CAPD Peritonitis in Adults |
|
|
196 | (1) |
|
Table 20A Anti-Tetanus Prophylaxis, Wound Classification, Immunization |
|
|
197 | (1) |
|
Table 20B Rabies Post-Exposure Prophylaxis |
|
|
198 | (1) |
|
Table 21 Selected Directory of Resources |
|
|
199 | (1) |
|
Table 22A Anti-Infective Drug-Drug Interactions |
|
|
200 | (7) |
|
Table 22B Drug-Drug Interactions Between Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIS) and Protease Inhibitors |
|
|
207 | (1) |
|
Table 23 List of Generic and Common Trade Names |
|
|
208 | (2) |
| Index Of Major Entities |
|
210 | |
